SINDU PHARMACEUTICALS
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 Jun 2009)
What this means for you
This application is over — abandoned 08 Jun 2009. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 78638080
- Mark type
- Stylized text
- Filed
- 26 May 2005
- Published for opposition
- 14 Feb 2006
- Abandoned
- 08 Jun 2009
- Attorney of record
- Jeffrey D. Hsi
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disorders
- Class 042 — Scientific and technological services: pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disorders
Owner
- Indus Pharmaceuticals, Inc., Andover, MA, US
- Indus Pharmaceuticals, Inc., Andover, MA, US
Prosecution history
- 08 Jun 2009 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
- 08 Jun 2009 — ABANDONMENT - NO USE STATEMENT FILED
- 07 Nov 2008 — SOU EXTENSION 5 GRANTED
- 07 Nov 2008 — SOU EXTENSION 5 FILED
- 07 Nov 2008 — SOU TEAS EXTENSION RECEIVED
- 09 May 2008 — SOU EXTENSION 4 GRANTED
- 09 May 2008 — SOU EXTENSION 4 FILED
- 09 May 2008 — SOU TEAS EXTENSION RECEIVED
- 06 Nov 2007 — SOU EXTENSION 3 GRANTED
- 06 Nov 2007 — SOU EXTENSION 3 FILED
- 06 Nov 2007 — SOU TEAS EXTENSION RECEIVED
- 26 Apr 2007 — SOU EXTENSION 2 GRANTED
- 26 Apr 2007 — SOU EXTENSION 2 FILED
- 26 Apr 2007 — SOU TEAS EXTENSION RECEIVED
- 09 Nov 2006 — SOU EXTENSION 1 GRANTED